Meeting
2015 ASCO Annual Meeting
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
Authors
Shaji Kumar
Mayo Clinic, Rochester, MN
Shaji Kumar , Ravi Vij , Jonathan L. Kaufman , Joseph Mikhael , Thierry Facon , Philippe Moreau , Martine Amiot , Stefanie Alzate , Lura J Morris , Jeremy A Ross , Martin Dunbar , Ming Zhu , Suresh K Agarwal , Joel Leverson , Sari H. Enschede , Rod Humerickhouse , Cyrille Touzeau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01794520
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8576)
DOI
10.1200/jco.2015.33.15_suppl.8576
Abstract #
8576
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Cyrille Touzeau
Poster
2016 ASCO Annual Meeting
Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
First Author: Shaji Kumar
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda